GUZI, Timothy, Kamil PARUCH, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Alan MALLAMS, Carmen ALVAREZ, Kartik KEERTIKAR, Jocelyn RIVERA, Tin-Yau CHAN, Vincent MADISON, Thierry FISCHMANN, Paul KIRSCHMEIER, Rajat BANNERJI, Lawrence DILLARD, Vinh TRAN, Zhenmin HE, Ray JAMES, Haengsoon PARK, Vidyadhar PARADKAR and Douglas HOBBS. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. 2008.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
Name in Czech Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
Authors GUZI, Timothy, Kamil PARUCH, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Alan MALLAMS, Carmen ALVAREZ, Kartik KEERTIKAR, Jocelyn RIVERA, Tin-Yau CHAN, Vincent MADISON, Thierry FISCHMANN, Paul KIRSCHMEIER, Rajat BANNERJI, Lawrence DILLARD, Vinh TRAN, Zhenmin HE, Ray JAMES, Haengsoon PARK, Vidyadhar PARADKAR and Douglas HOBBS.
Edition Number: WO 2008/130570 A1, Publisher: World Intellectual Property Organization, Place of publication: USA, Owner's name: Schering-Plough, 2008.
Other information
Original language English
Type of outcome Patent
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Science
Keywords (in Czech) cyclin dependent kinase; inhibitor; pyrazolopyrimidine; cancer
Keywords in English cyclin dependent kinase; inhibitor; pyrazolopyrimidine; cancer
Tags cancer, Cyclin dependent kinase, inhibitor, pyrazolopyrimidine
Changed by Changed by: doc. Mgr. Kamil Paruch, Ph.D., učo 108413. Changed: 23/6/2009 14:52.
Abstract
The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs such as cancer, were prepd. Thus, reacting II (prepn. given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 .mu.M and 0.029 .mu.M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compd. I alone or in combination with other therapeutic agents are claimed.
Abstract (in Czech)
viz anotace
PrintDisplayed: 5/5/2024 10:08